FDA Approved: OXERVATE — Supplemental Application (Domp farmaceutici S.p.A.)

View source ↗

Summary

FDA approves a supplemental application for Oxervate (cenegermin-bkbj) from Domp farmaceutici S.p.A., marking FDA approval of the requested supplemental change.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratitis

Drugs mentioned

• Oxervate (cenegermin)

Snippet

SUPPL AP for OXERVATE (CENEGERMIN-BKBJ)